Table 2 Bladder cancer stage distribution among non-diabetics and diabetic non-users and users of pioglitazone (Actos)
All patients | Diabetic subgroups | |||
|---|---|---|---|---|
Non diabetic | Diabetic | Pioglitazone non-users | Pioglitazone users | |
Stage: No. (%) | ||||
T0 | 18 (10.5) | 3 (9.1) | 2 (8.3) | 1 (11.1) |
Ta | 7 (4.1) | 1 (3) | 1 (4.2) | - |
Tis | 16 (9.3) | 2 (6) | 2 (8.3) | - |
T1 | 17 (9.9) | 2 (6) | 1 (4.2) | 1 (11.1) |
T2 | 38 (22.2) | 10 (30.3) | 7 (29.2) | 3 (33.3) |
T3 | 44 (25.7) | 10 (30.3) | 7 (29.2) | 3 (33.3) |
T4 | 31 (18.1) | 5 (15.2) | 4 (16.7) | 1 (11.1) |
Non muscle invasive | 58 (34) | 8 (24.2) | 6 (25) | 2 (22.2) |
Muscle invasive | 113 (66) | 25 (75.8) | 18 (75) | 7 (77.8) |
Node positive disease | 44 (25.7) | 11 (33.3) | 8 (33.3) | 3 (33.3) |